It's the last issue of Pharmaceutical Technology Focus in 2022, and a lot of changes have occurred over the year, not just in the pharma space, but also from a geopolitical, financial and energy perspective.

Most recently, after a tumultuous 45 days, Liz Truss resigned as the UK’s prime minister paving the way for Rishi Sunak to take on the mantle. In this issue, we talk to different stakeholders in the pharmaceutical space to gauge what the sector is hoping Sunak achieves in his tenure when it comes to funding, regulation, and relations with the European Union.

Drug shortages continue to affect medical care in healthcare systems, and experts tell us that supply bottlenecks for cardiovascular drugs are particularly concerning. Also in this issue, we explore how European countries plan to use electronic health records to improve health-related decision-making.

All this, and the latest pharma industry news, comment, data, and analysis from GlobalData.

Manasi Vaidya, editor

Go to article: Home | What Rishi Sunak can do for the UK pharma industry Go to article: In this issueGo to article: ContentsGo to article: CSafeGo to article: TripletreeGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: BEA TechnologiesGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: CommentGo to article: GSK speeds up the race to market first RSV vaccine for older adultsGo to article: Biden’s directive on foreign biotech investments impacts manufacturersGo to article: Novo Nordisk targets FDA approval for once-weekly insulin after Phase III dataGo to article: ‘Twindemic’ risks warrant immediate steps in Europe and the US Go to article: A game of two halves for Roche’s recently approved wet AMD assetsGo to article: Dr. Paul LohmannGo to article: NiproGo to article: In DepthGo to article: What Rishi Sunak can do for the UK pharma industryGo to article: Inside the European mass shift to data-driven health solutionsGo to article: Chronic drug shortages signal difficult outlook for cardiovascular careGo to article: Can gene therapies for haemophilia defend their high price tags?Go to article: Trial termination analysis unveils a silver lining for patient recruitmentGo to article: New dawn for the EU's joint procurement crisis responseGo to article: SkyepharmaGo to article: Bio Image Systems Inc.Go to article: In DataGo to article: The pharma industry found it easier to fill AI vacancies in Q3 2022 Go to article: Internet of things hiring levels in the pharma dropped in October 2022Go to article: Artificial intelligence hiring levels in the pharma dropped in October 2022Go to article: BaxterGo to article: EventsGo to article: Next issue